Adalimumab may reduce inflammation and pain and improve quality of life for patients with hidradenitis suppurativa (HS). HS is a chronic skin disease that occurs deep in the skin around oil glands and hair follicles causing red, tender bumps that often enlarge, break open and drain foul-smelling pus. HS is associated with pain and scarring, and often is resistant to treatment. Researchers conducted a phase 2, randomized, placebo-controlled trial to evaluate the efficacy and safety of adalimumab, an anti-tumor necrosis factor-α antibody, in 154 patients with moderate to severe HS...
via Health News from Medical News Today Read More Here..
No comments:
Post a Comment